Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6999) 6999
Publication (650) 650
Newsletter (108) 108
Book Review (91) 91
Book Chapter (37) 37
Newspaper Article (30) 30
Magazine Article (23) 23
Trade Publication Article (7) 7
Data Set (4) 4
Dissertation (4) 4
Conference Proceeding (3) 3
Transcript (2) 2
Government Document (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5825) 5825
male (3623) 3623
ribavirin (3543) 3543
female (3518) 3518
hepatitis c, chronic - drug therapy (3322) 3322
index medicus (3184) 3184
ribavirin - administration & dosage (3118) 3118
antiviral agents - administration & dosage (3104) 3104
middle aged (2987) 2987
drug therapy, combination (2783) 2783
adult (2732) 2732
antiviral agents - therapeutic use (2700) 2700
hepatitis c (2436) 2436
ribavirin - therapeutic use (2353) 2353
treatment outcome (2220) 2220
interferon-alpha - administration & dosage (2218) 2218
gastroenterology & hepatology (1811) 1811
interferon (1755) 1755
hepacivirus - genetics (1699) 1699
hepatitis c virus (1643) 1643
recombinant proteins (1643) 1643
interferon-alpha - therapeutic use (1632) 1632
genotype (1533) 1533
antiviral agents - adverse effects (1378) 1378
aged (1353) 1353
polyethylene glycols - administration & dosage (1255) 1255
therapy (1202) 1202
hepatitis c, chronic - virology (1173) 1173
hepatitis c - drug therapy (1163) 1163
ribavirin - adverse effects (1094) 1094
virus-infection (1064) 1064
infectious diseases (1060) 1060
hepatitis (1058) 1058
plus ribavirin (1046) 1046
infection (1040) 1040
hepacivirus - drug effects (995) 995
drug therapy (986) 986
health aspects (947) 947
interferon-alpha - adverse effects (944) 944
polyethylene glycols - therapeutic use (922) 922
pharmacology & pharmacy (882) 882
care and treatment (880) 880
viral load (875) 875
virology (855) 855
antiviral agents (776) 776
dosage and administration (741) 741
drug administration schedule (727) 727
rna, viral - blood (695) 695
hepatitis c, chronic - complications (664) 664
biological response modifiers (638) 638
infections (635) 635
hcv (622) 622
research (618) 618
risk factors (604) 604
animals (603) 603
sustained virological response (600) 600
combination therapy (598) 598
pegylated interferon (595) 595
recombinant proteins - administration & dosage (591) 591
virus diseases (583) 583
immunology (582) 582
viruses (560) 560
chronic hepatitis-c (557) 557
time factors (533) 533
analysis (527) 527
liver (522) 522
retrospective studies (520) 520
chronic hepatitis c (513) 513
adolescent (501) 501
genetic aspects (499) 499
polyethylene glycols - adverse effects (491) 491
recombinant proteins - therapeutic use (483) 483
dose-response relationship, drug (479) 479
antiviral agents - pharmacology (475) 475
medicine, general & internal (475) 475
sofosbuvir (473) 473
cirrhosis (472) 472
virus (468) 468
young adult (465) 465
microbiology (463) 463
combination (462) 462
hepacivirus - isolation & purification (451) 451
peginterferon alpha-2a (448) 448
peginterferon (447) 447
prospective studies (438) 438
initial treatment (420) 420
telaprevir (420) 420
recurrence (413) 413
patients (408) 408
genotype & phenotype (402) 402
gastroenterology and hepatology (399) 399
hiv infections - complications (399) 399
rna (390) 390
hepatitis c - virology (373) 373
interferons - administration & dosage (369) 369
hepatology (368) 368
efficacy (366) 366
antiviral therapy (364) 364
follow-up studies (364) 364
genotypes (364) 364
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6597) 6597
Spanish (87) 87
Japanese (85) 85
French (84) 84
German (84) 84
Russian (56) 56
Chinese (45) 45
Polish (38) 38
Korean (21) 21
Hungarian (20) 20
Croatian (14) 14
Italian (14) 14
Czech (10) 10
Serbian (9) 9
Portuguese (8) 8
Dutch (4) 4
Turkish (4) 4
Arabic (3) 3
Slovak (3) 3
Swedish (3) 3
Danish (2) 2
Hebrew (2) 2
Norwegian (2) 2
Bosnian (1) 1
Finnish (1) 1
Romanian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Management of direct-acting antiviral agent failures
by Buti, Maria and Riveiro-Barciela, Mar and Esteban, Rafael
Journal of Hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 6, pp. 1511 - 1522
Summary Failure to respond to the approved combinations of multiple direct-acting antiviral agents is relatively low in hepatitis C virus treatment... 
Gastroenterology and Hepatology | Daclatasvir | Simeprevir | Treatment | Resistance-associated variants | Ledipasvir | Interferon | Hepatitis C virus | Sofosbuvir | Direct-acting antivirals | Resistanceassociated variants | CHRONIC HCV | CHRONIC HEPATITIS-C | REAL-WORLD | PEGYLATED INTERFERON | DOUBLE-BLIND | GENOTYPE 1 INFECTION | INTERFERON-ALPHA 2A | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | DACLATASVIR PLUS SOFOSBUVIR | Uridine Monophosphate - administration & dosage | Humans | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Carbamates - administration & dosage | Simeprevir - administration & dosage | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Treatment Failure | Protease Inhibitors - administration & dosage | Fluorenes - administration & dosage | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Clinical Trials as Topic | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Interferons - administration & dosage | Drug Resistance, Viral - genetics | Anilides - administration & dosage | Sofosbuvir - administration & dosage | Uridine Monophosphate - analogs & derivatives | Macrocyclic Compounds - administration & dosage | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Development and progression | Protease inhibitors | Drug resistance | Hepatitis C | Proteases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System
by Ioannou, George N and Beste, Lauren A and Chang, Michael F and Green, Pamela K and Lowey, Elliot and Tsui, Judith I and Su, Feng and Berry, Kristin
Gastroenterology, ISSN 0016-5085, 2016, Volume 151, Issue 3, pp. 457 - 471.e5
Background & Aims We investigated the real-world effectiveness of sofosbuvir, ledipasvir/sofosbuvir, and paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD)... 
Gastroenterology and Hepatology | DAA | Harvoni | Viekira | VIRUS-INFECTION | RIBAVIRIN | LIVER-DISEASE | LEDIPASVIR | SUSTAINED VIROLOGICAL RESPONSE | HEPATOCELLULAR-CARCINOMA | CIRRHOSIS | GENOTYPE 1 INFECTION | HCV | GASTROENTEROLOGY & HEPATOLOGY | US VETERANS | Uridine Monophosphate - administration & dosage | Hepatitis C - drug therapy | United States | Humans | Middle Aged | Hepacivirus - genetics | Male | Carbamates - administration & dosage | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Female | Fluorenes - administration & dosage | Retrospective Studies | Ritonavir - administration & dosage | Genotype | Antiviral Agents - administration & dosage | Liver Cirrhosis - virology | Anilides - administration & dosage | Sofosbuvir - administration & dosage | Uridine Monophosphate - analogs & derivatives | Hepatitis C - virology | United States Department of Veterans Affairs | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | National health insurance | Hepatitis C | Drug therapy | Hepatitis C virus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real world cohort
by Calleja, Jose Luis and Crespo, Javier and Rincón, Diego and Ruiz-Antorán, Belén and Fernandez, Inmaculada and Perelló, Christie and Gea, Francisco and Lens, Sabela and García-Samaniego, Javier and Sacristán, Begoña and García-Eliz, María and Llerena, Susana and Pascasio, Juan Manuel and Turnes, Juan and Torras, Xavier and Morillas, Rosa Maria and Llaneras, Jordi and Serra, Miguel A and Diago, Moises and Fernández Rodriguez, Conrado and Ampuero, Javier and Jorquera, Francisco and Simon, Miguel A and Arenas, Juan and Navascues, Carmen Alvarez and Bañares, Rafael and Muñoz, Raquel and Albillos, Agustin and Mariño, Zoe and Spanish Grp Study Use and Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group
Journal of Hepatology, ISSN 0168-8278, 2017, Volume 66, Issue 6, pp. 1138 - 1148
Graphical abstract 
Gastroenterology and Hepatology | Antiviral agents | Ombitasvir | Ritonavir | Ledipasvir | Real-world | Genotype 1 | Paritaprevir | Sustained virologic response | Hepatitis C, Chronic | Sofosbuvir | Dasabuvir | Randomized controlled trials | PLUS RIBAVIRIN | VIRUS-INFECTION | CHRONIC HEPATITIS-C | SUSTAINED VIROLOGICAL RESPONSE | ALL-CAUSE MORTALITY | Chronic | HEPATOCELLULAR-CARCINOMA | TREATMENT-EXPERIENCED PATIENTS | Hepatitis C | GASTROENTEROLOGY & HEPATOLOGY | Uridine Monophosphate - administration & dosage | Humans | Middle Aged | Hepatitis C, Chronic - physiopathology | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Carbamates - administration & dosage | Neoplasm Recurrence, Local - etiology | Liver Neoplasms - etiology | Young Adult | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Fluorenes - administration & dosage | Carcinoma, Hepatocellular - etiology | Retrospective Studies | Drug Therapy, Combination | Glomerular Filtration Rate | Ritonavir - administration & dosage | Antiviral Agents - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Spain | Anilides - administration & dosage | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Sulfonamides - administration & dosage | Cohort Studies | Uracil - analogs & derivatives | Genetic aspects | Safety and security measures | Hepatitis C virus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus/hepatitis c virus genotype 1-coinfected patients treated in routine practice
by Bhattacharya, Debika and Belperio, Pamela S and Shahoumian, Troy A and Loomis, Timothy P and Goetz, Matthew B and Mole, Larry A and Backus, Lisa I
Clinical Infectious Diseases, ISSN 1058-4838, 06/2017, Volume 64, Issue 12, pp. 1711 - 1720
Background. Large cohorts are needed to assess human immunodeficiency virus (HIV)/hepatitis C virus (HCV) real-world treatment outcomes. We examined the... 
real-world | HCV | HIV | DAA | INFECTIOUS DISEASES | HIV/HCV | LEDIPASVIR-SOFOSBUVIR | CHRONIC HEPATITIS-C | MICROBIOLOGY | COINFECTED INDIVIDUALS | IMMUNOLOGY | INFECTION | COHORT | Uridine Monophosphate - administration & dosage | Anilides - therapeutic use | Hepatitis C - drug therapy | Coinfection - drug therapy | Veterans | Humans | Middle Aged | Fluorenes - therapeutic use | Hepacivirus - genetics | Male | Carbamates - administration & dosage | Practice Patterns, Physicians | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Female | Fluorenes - administration & dosage | Hepatitis C - complications | Registries | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Administration, Oral | Antiviral Agents - therapeutic use | HIV Infections - virology | Ribavirin - therapeutic use | Genotype | Treatment Outcome | Antiviral Agents - administration & dosage | Coinfection - virology | Macrocyclic Compounds - therapeutic use | Anilides - administration & dosage | Sofosbuvir - administration & dosage | Uridine Monophosphate - analogs & derivatives | HIV Infections - complications | Hepatitis C - virology | HIV Infections - drug therapy | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Carbamates - therapeutic use | Cohort Studies | Antiviral agents | Care and treatment | Dosage and administration | Hepatitis C | HIV infection
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection
by Laird, Melissa E and Mohsen, Amira and Duffy, Darragh and Mamdouh, Rasha and LeFouler, Lenaig and Casrouge, Armanda and El-Daly, Mai and Rafik, Mona and Abdel-Hamid, Mohamed and Soulier, Alexandre and Pawlotsky, Jean-Michel and Hézode, Christophe and Rosa, Isabelle and Renard, Philippe and Mohamed, Mostafa K and Bonnard, Philippe and Izopet, Jacques and Mallet, Vincent and Pol, Stanislas and Albert, Matthew L and Fontanet, Arnaud
Journal of Hepatology, ISSN 0168-8278, 2014, Volume 61, Issue 4, pp. 770 - 776
Background & Aims HCV requires host lipid metabolism for replication, and apolipoproteins have been implicated in the response to treatment. Methods We... 
Gastroenterology and Hepatology | Quantitative trait loci | IL28B | Lipid metabolism | Hepatitis C virus | Apolipoproteins | PARTICLES | BETA-2-GLYCOPROTEIN-I | RIBAVIRIN | PEGYLATED INTERFERON-ALPHA | LIPOPROTEIN-LIPASE | HCV INFECTION | GENETIC-VARIATION | LOW-DENSITY | SERUM-LIPIDS | GASTROENTEROLOGY & HEPATOLOGY | GENOME-WIDE ASSOCIATION | Coinfection | Hepatitis C - drug therapy | Humans | Middle Aged | Male | Viral Load | beta 2-Glycoprotein I - blood | HIV Infections - immunology | Hepatitis C - immunology | Interleukins - genetics | Ribavirin - administration & dosage | Adult | Female | Hepacivirus - physiology | Hepatitis C - complications | Hepacivirus - drug effects | Virus Replication - drug effects | Hepatitis C - genetics | Treatment Outcome | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Interferon-alpha - administration & dosage | beta 2-Glycoprotein I - genetics | HIV Infections - complications | HIV Infections - drug therapy | Hepatitis C - physiopathology | Aged | Polymorphism, Single Nucleotide | Genetic aspects | Health aspects | beta 2-Glycoprotein I/blood | Virus Replication/drug effects | HIV Infections/immunology | HIV Infections/drug therapy | Life Sciences | beta 2-Glycoprotein I/genetic | Immunology | Hepatitis C/complications Hepatitis | Polyethylene Glycols/administration & dosage | Interferon-alpha/administration & dosage | C/physiopathology Humans | Interleukins/genetics | Hepacivirus/physiology | C/drug therapy Hepatitis | C/immunology Hepatitis | HIV Infections/complications | Ribavirin/administration & dosage | Hepacivirus/drug effects | Antiviral Agents/administration & dosage | C/genetics Hepatitis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1: A Randomized Trial
by Sulkowski, Mark S and Eron, Joseph J and Wyles, David and Trinh, Roger and Lalezari, Jay and Wang, Chia and Slim, Jihad and Bhatti, Laveeza and Gathe, Joseph and Ruane, Peter J and Elion, Richard and Bredeek, Fritz and Brennan, Robert and Blick, Gary and Khatri, Amit and Gibbons, Krystal and Hu, Yiran B and Fredrick, Linda and Schnell, Gretja and Pilot-Matias, Tami and Tripathi, Rakesh and Da Silva-Tillmann, Barbara and McGovern, Barbara and Campbell, Andrew L and Podsadecki, Thomas
JAMA, ISSN 0098-7484, 03/2015, Volume 313, Issue 12, pp. 1223 - 1231
IMPORTANCE: Patients co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are at high risk for liver disease progression. However,... 
MEDICINE, GENERAL & INTERNAL | ABT-450/R-OMBITASVIR | VIREMIA | THERAPY | IMMUNODEFICIENCY-VIRUS INFECTION | PEGYLATED INTERFERON | ALPHA-2A PLUS RIBAVIRIN | GENOTYPE 1 INFECTION | COINFECTION | HCV | PREVALENCE | HIV-1 | Coinfection | Hepatitis C - drug therapy | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | Carbamates - administration & dosage | Ritonavir - adverse effects | Uracil - administration & dosage | Ribavirin - administration & dosage | Adult | Female | Hepatitis C - complications | Drug Therapy, Combination | Ritonavir - administration & dosage | Treatment Outcome | Macrocyclic Compounds - adverse effects | Antiviral Agents - administration & dosage | Pilot Projects | Uracil - adverse effects | Anilides - administration & dosage | Ribavirin - adverse effects | HIV Infections - complications | Sulfonamides - adverse effects | Carbamates - adverse effects | HIV Infections - drug therapy | Macrocyclic Compounds - administration & dosage | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Drugs | Clinical trials | Hepatitis | Human immunodeficiency virus--HIV | Medical treatment | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
by Jacobson, Ira M, Prof and Dore, Gregory J, Prof and Foster, Graham R, Prof and Fried, Michael W, Prof and Radu, Monica, MD and Rafalsky, Vladimir V, Prof and Moroz, Larysa, Prof and Craxi, Antonio, Prof and Peeters, Monika, MSc and Lenz, Oliver, PhD and Ouwerkerk-Mahadevan, Sivi, PhD and De La Rosa, Guy, MD and Kalmeijer, Ronald, MD and Scott, Jane, PhD and Sinha, Rekha, PhD and Beumont-Mauviel, Maria, PhD
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9941, pp. 403 - 413
Summary Background Although the addition of the HCV NS3/4A protease inhibitors boceprevir and telaprevir to pegylated interferon (peginterferon) alfa plus... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | IN-VITRO | IMPACT | TELAPREVIR | THERAPY | PROFILE | SAFETY | BOCEPREVIR | VIROLOGICAL RESPONSE | PEGINTERFERON | ONCE-DAILY TMC435 | Simeprevir | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Hepacivirus - genetics | Genotype | Male | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Ribavirin - administration & dosage | Sulfonamides - adverse effects | Adult | Female | Drug Therapy, Combination | Sulfonamides - administration & dosage | Patient outcomes | Interferon alpha | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Methods | Analysis | Clinical trials | Genetic aspects | Interferon | Biological response modifiers | Hepatitis C virus | Health aspects | Hepatitis | Genotype & phenotype | Infections
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
by Manns, Michael, Prof and Marcellin, Patrick, Prof and Poordad, Fred, Prof and de Araujo, Evaldo Stanislau Affonso, PhD and Buti, Maria, Prof and Horsmans, Yves, Prof and Janczewska, Ewa, MD and Villamil, Federico, Prof and Scott, Jane, PhD and Peeters, Monika, MSc and Lenz, Oliver, PhD and Ouwerkerk-Mahadevan, Sivi, PhD and De La Rosa, Guy, MD and Kalmeijer, Ronald, MD and Sinha, Rekha, PhD and Beumont-Mauviel, Maria, PhD
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9941, pp. 414 - 426
Summary Background Pegylated interferon (peginterferon) alfa 2a or 2b plus ribavirin regimens were the standard of care in patients with hepatitis C virus... 
Internal Medicine | Simeprevir | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Hepacivirus - genetics | Genotype | Male | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Heterocyclic Compounds, 3-Ring - administration & dosage | Ribavirin - administration & dosage | Adolescent | Adult | Female | Aged | Drug Therapy, Combination | Sulfonamides - administration & dosage | SUSTAINED VIROLOGICAL RESPONSE | MEDICINE, GENERAL & INTERNAL | IN-VITRO | TELAPREVIR | METAANALYSIS | PEGINTERFERON ALPHA-2B | TRIPLE THERAPY | BOCEPREVIR | ONE PILL | CHRONIC HCV INFECTION | ONCE-DAILY TMC435 | Patient outcomes | Interferon alpha | Drug therapy, Combination | Hepatitis C | Drug therapy | Methods | Ribavirin | Analysis | Clinical trials | Genetic aspects | Interferon | Product development | Biological response modifiers | Hepatitis C virus | Health aspects | Hepatitis | Mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease
by Pockros, Paul J and Reddy, K. Rajender and Mantry, Parvez S and Cohen, Eric and Bennett, Michael and Sulkowski, Mark S and Bernstein, David E and Cohen, Daniel E and Shulman, Nancy S and Wang, Deli and Khatri, Amit and Abunimeh, Manal and Podsadecki, Thomas and Lawitz, Eric
Gastroenterology, ISSN 0016-5085, 2016, Volume 150, Issue 7, pp. 1590 - 1598
Background & Aims Although hepatitis C virus (HCV) infection is common in patients with end-stage renal disease, highly efficacious, well-tolerated,... 
Gastroenterology and Hepatology | NS3/4A Protease Inhibitor | Renal Disease | RUBY-I | NS5A Inhibitor | UNITED-STATES | ABT-450/R-OMBITASVIR | RIBAVIRIN | SUSTAINED VIROLOGICAL RESPONSE | DIALYSIS PATIENTS | DASABUVIR | TREATMENT-EXPERIENCED PATIENTS | HEMODIALYSIS | HCV | CHRONIC KIDNEY-DISEASE | GASTROENTEROLOGY & HEPATOLOGY | Prospective Studies | Hepatitis C - drug therapy | Humans | Middle Aged | Hepacivirus - genetics | Male | Carbamates - administration & dosage | Dose-Response Relationship, Drug | Uracil - administration & dosage | Ribavirin - administration & dosage | Female | Hepatitis C - complications | Drug Therapy, Combination | Ritonavir - administration & dosage | Kidney Failure, Chronic - drug therapy | Genotype | Antiviral Agents - administration & dosage | Anilides - administration & dosage | Kidney Failure, Chronic - virology | Hepatitis C - virology | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Antiviral agents | Care and treatment | Chronic kidney failure | Analysis | Communicable diseases | Liver | Genetic aspects | Hepatitis C virus | Health aspects | Restaurants | Protease inhibitors | Proteases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Interferon-free therapies for chronic hepatitis C: Toward a hepatitis C virus-free world?
by Gentile, Ivan and Buonomo, Antonio Riccardo and Zappulo, Emanuela and Borgia, Guglielmo
Expert Review of Anti-Infective Therapy, ISSN 1478-7210, 2014, Volume 12, Issue 7, pp. 763 - 773
About 2% of the world's population is estimated to be chronically infected with hepatitis C virus (HCV). These chronic carriers are at risk of developing liver... 
Daclatasvir | MK-8742 | Ombitasvir | Interferon-free | Ledipasvir | MK-5172 | Asunaprevir | ABT-450 | Sofosbuvir | Dasabuvir | CONTROLLED-TRIAL | PLUS RIBAVIRIN | LIVER-TRANSPLANTATION | ombitasvir | asunaprevir | HCV INFECTION | daclatasvir | interferon-free | ledipasvir | sofosbuvir | SUSTAINED VIROLOGICAL RESPONSE | PROTEASE INHIBITOR | TREATMENT OPTIONS | GENOTYPE 1 INFECTION | PHARMACOLOGY & PHARMACY | dasabuvir | CHRONIC VIRAL-HEPATITIS | DISEASE PROGRESSION | Uridine Monophosphate - administration & dosage | Quinoxalines - adverse effects | Anilides - therapeutic use | Isoquinolines - adverse effects | Hepatitis C - drug therapy | Anilides - adverse effects | Humans | Imidazoles - administration & dosage | Benzofurans - administration & dosage | Carbamates - administration & dosage | Uracil - administration & dosage | Ribavirin - administration & dosage | Uridine Monophosphate - adverse effects | Imidazoles - therapeutic use | Hepatitis C - prevention & control | Quinoxalines - therapeutic use | Uridine Monophosphate - therapeutic use | Disease Eradication | Benzofurans - therapeutic use | Quinoxalines - administration & dosage | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Ribavirin - therapeutic use | Uracil - therapeutic use | Clinical Trials as Topic | Macrocyclic Compounds - adverse effects | Antiviral Agents - administration & dosage | Benzofurans - adverse effects | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Anilides - administration & dosage | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Isoquinolines - therapeutic use | Sulfonamides - adverse effects | Carbamates - adverse effects | Macrocyclic Compounds - administration & dosage | Carbamates - therapeutic use | Hepacivirus | Isoquinolines - administration & dosage | Drug Combinations | Sulfonamides - administration & dosage | Uracil - analogs & derivatives
Journal Article
Details down arrow
11. Full Text Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial
by Mizokami, Masashi, Prof and Yokosuka, Osamu, Prof and Takehara, Tetsuo, Prof and Sakamoto, Naoya, Prof and Korenaga, Masaaki, MD and Mochizuki, Hitoshi, MD and Nakane, Kunio, MD and Enomoto, Hirayuki, MD and Ikeda, Fusao, MD and Yanase, Mikio, MD and Toyoda, Hidenori, MD and Genda, Takuya, MD and Umemura, Takeji, MD and Yatsuhashi, Hiroshi, Prof and Ide, Tatsuya, MD and Toda, Nobuo, MD and Nirei, Kazushige and Ueno, Yoshiyuki, Prof and Nishigaki, Yoichi, MD and Betular, Juan, BS and Gao, Bing, PhD and Ishizaki, Akinobu, BA and Omote, Masa, PhD and Mo, Hongmei, MD and Garrison, Kim, PhD and Pang, Phillip S, MD and Knox, Steven J, BS and Symonds, William T, PharmD and McHutchison, John G, MD and Izumi, Namiki, Prof and Omata, Masao, Prof
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 6, pp. 645 - 653
Summary Background Compared with other countries, patients with chronic hepatitis C infection in Japan tend to be older, have more advanced liver disease, and... 
Infectious Disease | INFECTIOUS DISEASES | SIMEPREVIR | INFECTION | CHRONIC HCV | Uridine Monophosphate - administration & dosage | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Young Adult | Benzimidazoles - administration & dosage | Time Factors | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Fluorenes - administration & dosage | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Hepacivirus - isolation & purification | Administration, Oral | Japan | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Asian Continental Ancestry Group | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Liver | Dosage and administration | Product development | Drug therapy, Combination | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Hepatitis | Genotype & phenotype | Liver cancer | Heart attacks | Liver diseases | Human immunodeficiency virus--HIV | Hepatology | Response rates | Interferon | Infections | Drug dosages | Patients
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights